What they make
2 inputs Cryoport supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Cryoport makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Biopharma Services
59%Life Sciences Products (MVE Biological Solutions)
41%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2021
Cryoport — publicly known as the specialized cold-chain logistics company that ships every FDA-approved CAR-T cancer therapy — also owns MVE Biological Solutions, the largest US manufacturer of liquid nitrogen storage dewars for commercial livestock artificial insemination programs. The same MVE product line that stores CAR-T drug substance at -196°C at cell therapy manufacturing sites also stores bull semen in 30,000 cattle breeding operations across the US. A manufacturing disruption at MVE's Augusta, Georgia facility would simultaneously affect CAR-T drug substance storage capacity and cattle genetics supply chains nationwide.
Cryoport Inc. ↗Chokepoint2018
Cryoport has become the near-sole-source logistics provider for commercial autologous CAR-T therapies (Kite/Gilead Yescarta, Bristol Myers Squibb Breyanzi). Each CAR-T infusion requires a unique N=1 patient-specific round trip in liquid-nitrogen vapor-phase containers (-196°C). With cryogenic logistics representing 20–40% of total CAR-T supply chain cost and treatments priced near $1 million, a Cryoport disruption or container shortage would halt treatment delivery industry-wide.
BioSpace ↗Capacity2024
Cryoport Systems' cryogenic shipper network is deeply embedded in the CAR-T supply chain: the company's ShipperStat platform tracks over 40,000 active cryogenic shippers at any given time, supporting logistics for all five FDA-approved autologous CAR-T therapies as well as dozens of clinical-stage cell and gene therapy programs. Each autologous CAR-T treatment requires a minimum of two cryogenic shipments (leukapheresis material to manufacturing site; finished CAR-T product to infusion site), meaning every new CAR-T patient approval translates directly to a new Cryoport shipper demand event. As CAR-T indications expand from lymphoma to myeloma to solid tumors, Cryoport's logistics volume scales proportionally.
Cryoport Inc. ↗Origin2021
Cryoport began as a pure cold-chain logistics startup founded in 2005 in San Diego, operating a single reusable cryogenic shipper product for academic and small biotech clients. The company went public on NASDAQ (CYRX) in 2009 and grew gradually alongside the cell therapy industry. The strategic transformation came through two large acquisitions in 2021: CRYOPDP ($480M, French cold-chain logistics) and MVE Biological Solutions ($320M, US cryogenic hardware manufacturer). Within 12 months, Cryoport transformed from a logistics-only company into an integrated cold-chain platform spanning logistics services + hardware manufacturing. Total 2021 acquisition spend of ~$800M against a pre-acquisition market cap of ~$2B.
Cryoport Inc. ↗